GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eliem Therapeutics Inc (NAS:ELYM) » Definitions » Earnings Yield (Joel Greenblatt) %

Eliem Therapeutics (Eliem Therapeutics) Earnings Yield (Joel Greenblatt) % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eliem Therapeutics Earnings Yield (Joel Greenblatt) %?

Eliem Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $-28.84 Mil. Eliem Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.84 Mil. Eliem Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Eliem Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

ELYM' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11176.97   Med: 0   Max: 10418.05
Current: -33.44

During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Eliem Therapeutics was 10418.05%. The lowest was -11176.97%. And the median was 0.00%.

ELYM's Earnings Yield (Joel Greenblatt) % is ranked worse than
66.9% of 1414 companies
in the Biotechnology industry
Industry Median: -15.29 vs ELYM: -33.44

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Eliem Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Eliem Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Eliem Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eliem Therapeutics Earnings Yield (Joel Greenblatt) % Chart

Eliem Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- - -25.84 175.44 126.58

Eliem Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 181.82 181.82 128.21 126.58 -

Competitive Comparison of Eliem Therapeutics's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Eliem Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eliem Therapeutics's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eliem Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Eliem Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.



Eliem Therapeutics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Eliem Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-40.275/-31.66062
=127.21 %

Eliem Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.84 Mil.



Eliem Therapeutics  (NAS:ELYM) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Eliem Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Eliem Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eliem Therapeutics (Eliem Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
23515 NE Novelty Hill Road, Suite B221 No. 125, Redmond, WA, USA, 98053
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
Executives
Emily Pimblett officer: Chief Accounting Officer C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Ai Eti Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Judith Dunn director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Valerie Morisset officer: Chief Scientific Officer C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Andrew David Levin director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Simon Tate director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Adam Joseph Rosenberg director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
James B Bucher officer: EVP and General Counsel 11804 NORTH CREEK PARKWAY S, BOTHELL WA 98011
Ra Capital Nexus Fund Ii, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Erin Lavelle officer: COO & CFO C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Len Blavatnik other: Affiliate of 10% Owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
Liam Ratcliffe director C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Robert Azelby director, officer: Chief Executive Officer 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109